Exforge antitrust settlement caps Novartis’ year of legal disputes
Pharmaceutical Technology
JANUARY 6, 2023
Last year, Novartis began with a win in January, as the US Court of Appeals affirmed the validity of Gilenya’s patent, allowing the company to sue a competitor generics company for filing for FDA approval for its Gilenya generic. Gilenya is an oral medication for multiple sclerosis. Fighting Entresto generics.
97 
Let's personalize your content